French ANSM to boost EU role, safety monitoring and access to innovation
This article was originally published in Scrip
Executive Summary
The French regulatory agency ANSM says that this year it plans to play a greater role in EU drug regulatory activities, improve patients' access to innovative drugs, and strengthen the monitoring of certain product classes including antibiotics and benzodiazepines. It will also step up safety evaluations of some specific medicines and high-risk medical devices, and increase transparency at the agency.